Diagnosis of Endometriosis: Proteomics

Andrew N. Stephens, Luk Rombauts, Lois A. Salamonsen
In: Endometriosis · 2011 · pp. 324–335 · doi:10.1002/9781444398519.ch31 · W1595970702
other OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Proteomics aims to identify diagnostic markers for endometriosis, facing challenges with abundant proteins, sample choice, and classification, but advances in fractionation and bio-informatics offer potential for less invasive detection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Proteomics techniques have been applied to identify proteins for development as diagnostic markers of endometriosis, but to date most studies have been unable to overcome the presence of highly abundant proteins. The main issues to be resolved include the choice of sample for discovery of new markers (eutopic or ectopic tissue, peritoneal fluid, uterine lavage fluid or blood) and the classification of test samples. The application of emerging fractionation techniques to capture and concentrate low-abundance proteins, new non-gel-based proteomic technologies and various protein labeling strategies combined, and the ongoing development of advanced bio-informatics tools should enable progress towards the development of relatively non-invasive diagnostic methods for this disease.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK